Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.61 |
| ▸ | FGF1 | P05230 | 1/20 | 0.52 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | VEGFA | P15692 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519931 | 0.99 | MDK (0.62) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20519905 | 0.99 | MDK (0.62) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20520177 | 0.98 | MDK (0.64) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20520078 | 0.98 | MDK (0.64) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20519810 | 0.97 | MDK (0.60) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20519819 | 0.97 | MDK (0.60) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL20520126 | 0.97 | MDK (0.60) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL23126141 | 0.96 | MDK (0.59) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL23126071 | 0.96 | HPSE (0.56) | MDKFGF1FGF2VEGFAHPSE | |
| SCHEMBL23126137 | 0.94 | HPSE (0.58) | MDKFGF1FGF2VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | MDK 2412/4885FGF1 4232/4885FGF2 4081/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | MDK 2412/4885FGF1 4232/4885FGF2 4081/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | MDK 2412/4885FGF1 4232/4885FGF2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.